Simone Zanella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simone Zanella has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Arianna Pina
Università degli Studi di Milano, Dipartimento di Chimica, Via C. Golgi, 19, I-20133, Milan, Italy
1 shared publication Aurelio Marsiglio
Nerviano Medical Sciences (NMS), Via Pasteur 10, 20014, Nerviano, Italy
1 shared publication- Cesare Gennari
Università degli Studi di Milano
1 shared publication Clara Albanese
Nerviano Medical Sciences (NMS), Via Pasteur 10, 20014, Nerviano, Italy
1 shared publication- Clelia Giannini
Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milan, Italy
1 shared publication - Daniela Arosio
Istituto di Scienze e Tecnologie Chimiche (SCITEC) ‘Giulio Natta’, Consiglio Nazionale Delle Ricerche (CNR), Via C. Golgi 19, Milan 20133, Italy
1 shared publication
Latest Publications
- 7 February 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 367 (6478) , 676-681
Total synthesis of the complex taxane diterpene canataxpropellane
Synthesis of Taxol's complicated cousin: Propellane molecules contain three rings that all share a common edge, thereby collectively resembling a propeller. Canataxpropellane, a yew-derived natural product related to the cancer drug Taxol, is unusual in that it has two different propellane motifs in its backbone. Schneider et al. report a chemical synthesis of this intricate compound in under 30 steps. Key features of the route include a Diels-Alder reaction rendered asymmetric by introduction of a chiral silyl auxiliary, followed by a photochemical cycloaddition to establish the cyclobutane core. Science , this issue p. 676
- 7 February 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 367 (6478) , 676-681
Total synthesis of the complex taxane diterpene canataxpropellane
Synthesis of Taxol's complicated cousin: Propellane molecules contain three rings that all share a common edge, thereby collectively resembling a propeller. Canataxpropellane, a yew-derived natural product related to the cancer drug Taxol, is unusual in that it has two different propellane motifs in its backbone. Schneider et al. report a chemical synthesis of this intricate compound in under 30 steps. Key features of the route include a Diels-Alder reaction rendered asymmetric by introduction of a chiral silyl auxiliary, followed by a photochemical cycloaddition to establish the cyclobutane core. Science , this issue p. 676
- Open Access
- 26 May 2017
- Published by Wiley in Chemistry – A European Journal
- Vol. 23 (33) , 7910-7914
Tumor Targeting with an isoDGR–Drug Conjugate
Herein we report the first example of an isoDGR–drug conjugate (2), designed to release paclitaxel selectively within cancer cells expressing integrin αVβ3. Conjugate 2 was synthesized by connecting the isoDGR peptidomimetic 5 with paclitaxel via the lysosomally cleavable Val–Ala dipeptide linker. Conjugate 2 displayed a low nanomolar affinity for the purified integrin αVβ3 receptor (IC50=11.0 nm). The tumor targeting ability of conjugate 2 was assessed in vitro in anti‐proliferative assays on two isogenic cancer cell lines characterized by different integrin αVβ3 expression: human glioblastoma U87 (αVβ3+) and U87 β3‐KO (αVβ3−). The isoDGR‐PTX conjugate 2 displayed a remarkable targeting index (TI=9.9), especially when compared to the strictly related RGD‐PTX conjugate 4 (TI=2.4).
- 26 May 2017
- Published by Wiley in Chemistry – A European Journal
- Vol. 23 (33) , 7910-7914
Open AccessTumor Targeting with an isoDGR–Drug Conjugate
Herein we report the first example of an isoDGR–drug conjugate (2), designed to release paclitaxel selectively within cancer cells expressing integrin αVβ3. Conjugate 2 was synthesized by connecting the isoDGR peptidomimetic 5 with paclitaxel via the lysosomally cleavable Val–Ala dipeptide linker. Conjugate 2 displayed a low nanomolar affinity for the purified integrin αVβ3 receptor (IC50=11.0 nm). The tumor targeting ability of conjugate 2 was assessed in vitro in anti‐proliferative assays on two isogenic cancer cell lines characterized by different integrin αVβ3 expression: human glioblastoma U87 (αVβ3+) and U87 β3‐KO (αVβ3−). The isoDGR‐PTX conjugate 2 displayed a remarkable targeting index (TI=9.9), especially when compared to the strictly related RGD‐PTX conjugate 4 (TI=2.4).